Cyclical breast pain. Disorders of breast
Conditions
Interventions
Intervention 1: The control group will receive 25 gr placebo of flaxseed daily and placebo tablet of vitex agnus twice a day for two menstrual cycles. Intervention 2: The first intervention group wil
Placebo
Treatment - Drugs
The control group will receive 25 gr placebo of flaxseed daily and placebo tablet of vitex agnus twice a day for two menstrual cycles.
The first intervention group will recieve tablet of vitex agnus made by Goldaru pharmaceutical company in Esfahan (contain 3.2- 4.8 mg dry extract of vitex fruit, equal 0.42-0.58 mg Aucubin) twice a d
The second intervention group will recieve 25 grams of flaxseed powder in a cup of water daily plus placebo tablet of vitex agnus twice a day for two menstrual cycles.
Sponsors
Vice chancellor for research, Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Complaint of cyclical breast pain and tenderness; aged 18 to 45 years; Not currently taking hormonal contraception; having regular menstrual cycles (cycles 22 to 35 days) in the last 6 months; having a phone number for following; willingness to participate in study and having informed consent; being literate; cyclical breast pain and pain severity score above 7 according to chart Cardiff. Exclusion criteria: History of breast cancer; History of injury or wound in breast; using of medications that affect on breast pain (anti-depressants, digoxin, methyldopa, spironolactone, Chlorpropamide, danazol and tamoxifen); existence of lump or abnormalities in breast examination; existence of non cyclical breast pain or pain originates outside of the breast; history of asthma or allergies; taking dopamin agonist and antagonist (Levodopa, Amphetamine, Amphetamine, pergolide, Cabergoline, metoclopramide) in the last 6 months; history of breast cancer and other cancers in first-degree relatives; existence of known uterine myoma.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration and severity of breast pain. Timepoint: Before intervention, 1 and 2 months after intervention. Method of measurement: Cardiff chart. | — |
Secondary
| Measure | Time frame |
|---|---|
| Menstrual bleeding. Timepoint: Before intervention, 1 and 2 months afterintervention. Method of measurement: Higham chart.;Perimenstrual symptoms. Timepoint: Before intervention, 1 and 2 months after intervention. Method of measurement: Shortened premenstrual assessment form. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmadpur Parivash
Faculty of Nursing & Midwifery, Tabriz University of Medical Sciences
Outcome results
None listed